MARAbio
Michael Paul is currently the CEO, President, and Member Board of Directors at MARABio, Inc. Michael is also involved in various other companies such as Support, Inc., Applied Biosensors, Trucyto Biosciences, Petra Capital Partners, Circular Genomics, Bionano Genomics, Lineagen, vSpring Capital, Mesa Verde Venture Partners, and Lineagen Research Corporation in different roles focused on biotechnology and healthcare. Michael has a Ph.D. in Biochemistry/Molecular Biology from the University of Utah and a Bachelor of Arts in Biology/Biological Sciences from Colby College.
MARAbio
We identify the risk of developing Maternal Autoantibody Related Autism (MARA), a subtype of autism that is estimated to represent approximately 20% of overall cases, through a new type of risk assessment test for prospective mothers prior to (but not during) pregnancy, and for mothers during the early postnatal period. Our goal is to provide families with options to materially reduce the occurrence or severity of MARA. Our precision technology uses a blood test in women to identify the presence of a distinct cluster of autoantibodies that lead to MARA, thereby enabling the earliest risk assessment for the development of autism in a child.